DY131

€70.00

Excl. VAT

Item no.	M3764-5mg
Manufacturer	AbMole
Amount	5mg
Category	Neuroscience Neural Lineage Markers Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules S100 Calcium Binding Protein B Markers
Type	Inhibitors
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK 9089
Available
Cas #	95167-41-2
Bioactivity information	DY131 appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists. Sox2-Cre:Errbeta+/lox and Sox2-Cre:Errbetalox/lox mice treated with the Errbeta and Errgamma agonist DY131 demonstrated increased corticotropin-releasing hormone (Crh) expression in the paraventricular nucleus of the hypothalamus, although corticosterone levels were not affected. Adrenal Cyp11b1 and Cyp11b2 mRNA were increased in pregnant WT mice treated with DY131. In this study, using RNA knockdown and transcriptional activation with DY131 (an ERRgamma agonist), we clearly demonstrated that ERRgamma promotes hormone production and cell fusion indicating that ERRgamma is a key positive transcriptional factor involved in CT differentiation.
Target	Estrogen Receptor
Synonyms	GSK 9089
MW	311, 38
Formula	C18H21N3O2
Solubility	DMSO 100 mg/mL, Ethanol 10 mg/mL
Purity	>98%

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M3764-5mg-safety-datasheet.pdf